Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK ALK F1174C ALK V1180L |
| Therapy | Bevacizumab + Lorlatinib |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK ALK F1174C ALK V1180L | lung adenocarcinoma | predicted - sensitive | Bevacizumab + Lorlatinib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Lorbrena (lorlatinib) and Avastin (bevacizumab) resulted in a partial response and a progression-free survival of 33 months in a patient with lung adenocarcinoma harboring EML4-ALK (e6:e20) with ALK F1174C and V1180L (PMID: 38978737). | 38978737 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38978737) | Case report: Precise NGS and combined bevacizumab promote durable response in ALK-positive lung adenocarcinoma with multiple-line ALK-TKI resistance. | Full reference... |